Combination lipid therapy in type 2 diabetes mellitus

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2011-05-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.2011.558503PMID 21323502
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combination Lipid Therapy in Type 2 Diabetes

  2011cited by this paper
• Associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study

  2010cited by this paper
• [Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study].

  2010cited by this paper
• Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

  2010cited by this paper
• Combination lipid therapy in type 2 diabetes.

  2010cited by this paper
• Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

  2010cited by this paper
• "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study

  2010cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cited by this paper
• Effects of combination lipid therapy in type 2 diabetes mellitus.

  2010cited by this paper
• Safety of anacetrapib in patients with or at high risk for coronary heart disease.

  2010cited by this paper
• Mechanisms for therapeutic correction of dyslipidaemia in insulin resistance and diabetes.

  2010cited by this paper
• Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230))

  2010cited by this paper
• Supplementary webappendix

  2009cited by this paper
• Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

  2009cited by this paper
• Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

  2009cited by this paper
• Lipid modification in type 2 diabetes: the role of LDL and HDL

  2009cited by this paper
• Extended-release niacin or ezetimibe and carotid intima-media thickness.

  2009cited by this paper
• Marine ω-3 Fatty Acid Intake

  2009cited by this paper
• Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.

  2008cited by this paper
• Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.

  2008cited by this paper
• Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome

  2008cited by this paper
• Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study

  2008cited by this paper
• Effects of niacin on glucose control in patients with dyslipidemia.

  2008cited by this paper
• The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

  2007cited by this paper
• HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.

  2007cited by this paper
• Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).

  2007cited by this paper
• Effects of torcetrapib in patients at high risk for coronary events.

  2007cited by this paper
• Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study

  2007cited by this paper
• Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

  2006cited by this paper
• A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

  2006cited by this paper
• Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

  2006cited by this paper
• Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials

  2006cited by this paper
• Diabetic dyslipidaemia: insights for optimizing patient management

  2005influential reference
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes

  2005cited by this paper
• Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.

  2005cited by this paper
• Fenofibrate: metabolic and pleiotropic effects.

  2005cited by this paper
• New insight into the pathophysiology of lipid abnormalities in type 2 diabetes.

  2005cited by this paper
• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  2005cited by this paper
• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  2005cited by this paper
• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

  2004cited by this paper
• Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

  2004cited by this paper
• Omega 3 fatty acids for prevention and treatment of cardiovascular disease.

  2004cited by this paper
• Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.

  2004cited by this paper
• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

  2003cited by this paper
• Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease: The Diabetes Atherosclerosis Intervention Study (DAIS)

  2003cited by this paper
• Diabetic dyslipidaemia: from basic research to clinical practice*

  2003cited by this paper
• Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).

  2003cited by this paper
• Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

  2002cited by this paper
• Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans

  2002cited by this paper
• Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

  2002cited by this paper
• Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.

  2002cited by this paper
• Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus

  2002cited by this paper
• Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

  2001cited by this paper
• The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

  2001cited by this paper
• Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

  2001cited by this paper
• Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

  2001cited by this paper
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

  2000cited by this paper
• Metabolic abnormalities of apolipoprotein B‐containing lipoproteins in non‐insulin‐dependent diabetes: a stable isotope kinetic study

  2000cited by this paper
• Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients

  2000cited by this paper
• LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study.

  2000cited by this paper
• Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.

  2000cited by this paper
• Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

  2000cited by this paper
• MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION

  2000cited by this paper
• Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

  1999cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes

  1999cited by this paper
• The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk.

  1999cited by this paper
• Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

  1998cited by this paper
• Fish Oil and Glycemic Control in Diabetes: A meta-analysis

  1998cited by this paper
• Mechanism of action of fibrates on lipid and lipoprotein metabolism.

  1998cited by this paper
• Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

  1998cited by this paper
• Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.

  1998cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

  1997cited by this paper
• Dyslipidemia and Hyperglycemia Predict Coronary Heart Disease Events in Middle-Aged Patients With NIDDM

  1997cited by this paper
• Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes

  1989cited by this paper
• Diabetes and atherosclerosis: an epidemiologic view.

  1987cited by this paper
• Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

  1986cited by this paper
• Five-year incidence of major macrovascular complications in diabetes mellitus.

  1985cited by this paper
• Five-year incidence of major macrovascular complications in diabetes mellitus.

  1985cited by this paper
• The Role of Circulating Glucose and Triglyceride Concentrations and Their Interactions with Other “Risk Factors” as Determinants of Arterial Disease in Nine Diabetic Population Samples from the WHO Multinational Study

  1983cited by this paper
• Coronary Drug Project Research Group.

  1978cited by this paper
• Clofibrate and niacin in coronary heart disease.

  1975cited by this paper
• Vascular Health and Risk Management Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Review of Extended-release Niacin/laropiprant Fixed Combination in the Treatment of Mixed Dyslipidemia and Primary Hypercholesterolemia

  year unknowncited by this paper

• Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease

  2026cites this paper
• The effect of online health management on type 2 diabetes mellitus: A systematic review and meta-analysis.

  2025cites this paper
• A Meta-Analysis of the Effectiveness of Telemedicine in Glycemic Management among Patients with Type 2 Diabetes in Primary Care

  2022cites this paper
• Chapitre 19 – Les complications chroniques du diabète

  2014cites this paper
• Current world literature.

  2012cites this paper
• Argan Oil Exerts an Antiatherogenic Effect by Improving Lipids and Susceptibility of LDL to Oxidation in Type 2 Diabetes Patients

  2011cites this paper
• Effects of intensive blood-pressure control in type 2 diabetes mellitus.

  2010cites this paper
• Effects of medical therapies on retinopathy progression in type 2 diabetes.

  2010cites this paper